読み込み中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新データ
$22.09
−$0.02 · -0.09%
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
前日終値
$22.09
−$0.02 · -0.09%
時間外
$21.28
−$0.81 · -3.67%
10月9日 18:43 ET
日中の時刻はETです。市場データは遅延する場合があります。
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
日中レンジ
現在 $22.09
52週レンジ
現在 $22.09
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
98
大幅な割安
センチメント
60
まちまち
リスク
44
やや高いリスク
モメンタム
40
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
日中レンジ
現在 $22.09
52週レンジ
現在 $22.09
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 7.81億 USD | 6.31億 USD | 5.67億 USD | 4.64億 USD | 2.77億 USD |
| 売上原価 | 3.17億 USD | 2.54億 USD | 2.41億 USD | 2.54億 USD | 1.26億 USD |
| 粗利益 | 4.63億 USD | 3.77億 USD | 3.26億 USD | 2.09億 USD | 1.51億 USD |
| 研究開発 | — | — | — | 398.3万 USD | 945.1万 USD |
| 販売・一般管理 | 2.76億 USD | 1.83億 USD | 1.59億 USD | 1.72億 USD | 1.19億 USD |
| 営業費用 | 2.76億 USD | 2.07億 USD | 1.59億 USD | 1.76億 USD | 1.33億 USD |
| 受取利息 | 1128.9万 USD | 1397.6万 USD | 1561.5万 USD | 104.7万 USD | 1.2万 USD |
| 支払利息 | 8231.2万 USD | 7397.4万 USD | 8333.9万 USD | 6321.3万 USD | 2101.4万 USD |
| 減価償却費と償却費 | 2.26億 USD | 1.69億 USD | 1.49億 USD | 1.39億 USD | 6891.7万 USD |
| 営業利益 | 1.87億 USD | 1.7億 USD | 1.67億 USD | 3331.9万 USD | 1762.8万 USD |
| 純利益 | 6287万 USD | 6919万 USD | 4815.5万 USD | −2500.2万 USD | 7151.7万 USD |
会社概要が更新されました 2026年10月10日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2406.75万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM1907.36万0.02%782.66億 USD0.19%$278.94+0.49%
Invesco Pharmaceuticals ETFPJP1423.17万2.63%5.41億 USD0.58%$122.88+1.56%
Avantis U.S. Small Cap Value ETFAVUV1050.55万0.03%308.25億 USD0.25%$119.64-0.41%
Invesco Biotechnology & Genome ETFPBE942.31万2.30%4.1億 USD0.59%$97.065+2.98%
Vanguard Extended Market ETFVXF925.14万0.01%954億 USD0.05%$235+0.80%
State Street SPDR S&P Pharmaceuticals ETFXPH851.57万1.88%4.62億 USD0.35%$64.65+1.60%
Pacer US Small Cap Cash Cows ETFCALF682.54万0.19%35.94億 USD0.59%$54.66-0.16%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMInvesco Pharmaceuticals ETFPJPAvantis U.S. Small Cap Value ETFAVUVInvesco Biotechnology & Genome ETFPBEVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHPacer US Small Cap Cash Cows ETFCALFAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
